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Abstract
Background:  The  increasing  resistance  to  quinolones  has  led  to  the  consideration  of  other  antibi-
otic options  for  the  prevention  of  infectious  complications  in  prostate  biopsy.  We  present  our
experience  using  a  single  dose  of  piperacillin/tazobactam  as  prophylaxis.
Methods:  A  retrospective  study  of  transrectal  prostate  biopsies  performed  at  our  institution
from 2008  to  2013  was  conducted.  All  patients  received  enemas  before  biopsy  and  a  single  4.5  g
dose of  piperacillin/tazobactam  was  administered  i.v.  a  few  minutes  before  the  biopsy.  Clinical
and microbiological  variables  were  analyzed  to  ﬁnd  out  risk  factors  for  complications.
Results:  A  total  of  543  biopsies  were  included.  Ninety-two  complications  (16.9%)  were  reported
in 74  (13.6%)  patients,  4.2%  of  which  were  infectious  complications.  In  these  patients,  the
associated  risk  factors  were  a  previous  history  of  positive  urine  cultures  within  a  3-year  period
before biopsy,  the  presence  of  a  transurethral  indwelling  catheter  at  the  time  of  the  biopsy,
hospital  admission  within  a  month  before  biopsy,  and  a  preoperative  positive  urine  culture
despite antibiotic  therapy  selected  according  to  the  resistance  pattern.
Conclusions:  Physicians  and  patients  should  be  aware  of  the  risk  for  complications,  particularly
if risk  factors  are  present.  A  single  dose  of  piperacillin/tazobactam  is  a  reasonable  option  for
prophylaxis,  especially  in  countries  with  a  high  prevalence  of  quinolone-resistant  pathogens.
© 2015  The  Authors.  Published  by  Masson  Doyma  México  S.A.  on  behalf  of  Sociedad
Mexicana de  Urología.  This  is  an  open  access  article  under  the  CC  BY-NC-ND  license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).∗ Corresponding author at: Department of Urology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga
5, Col. Seccion XVI, Tlalpan 14000, Mexico City, Mexico. Teléfono: +52 55 54870900x7252.
E-mail address: frodriguez.covarrubias@gmail.com (F. Rodriguez-Covarrubias).
ttp://dx.doi.org/10.1016/j.uromx.2015.07.003
007-4085/© 2015 The Authors. Published by Masson Doyma México S.A. on behalf of Sociedad Mexicana de Urología. This is an open access
rticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Biopsias  Transrectales  de  Próstata  usando  Proﬁlaxis  con  Dosis  Única  de
Piperacilina/Tazobactam
Resumen
Objetivo:  El  objetivo  de  este  estudio  es  analizar  el  desempen˜o  de  piperacilina/tazobactam
dosis única  como  proﬁlaxis  para  biopsias  de  próstata  transrectales,  así  como  conocer  los  factores
de riesgo  asociados  a  complicaciones  en  una  región  con  alta  tasa  de  resistencia  a  quinolonas.
Materiales and  Métodos: Estudio  retrospectivo  que  incluyó  todas  las  biopsias  de  próstata  real-
izadas en  nuestro  instituto  de  2008--2013.  Todos  los  pacientes  recibieron  2  enemas  antes  de  las
biopsias y  una  dosis  de  4.5gr  de  piperacilina/tazobactam  I.V.  antes  de  la  biopsia.  Se  incluyó
múltiples variables  y  se  hizo  énfasis  en  las  complicaciones  presentadas.  Se  realizó  un  análisis
estadístico  descriptivo  y  se  buscó  asociaciones  de  posibles  factores  de  riesgo.
Resultados:  Se  incluyó  543  biopsias.  Se  reportó  92  (16.9%)  complicaciones  en  74  (13.6%)
pacientes. Veintitrés  (4.2%)  pacientes  tuvieron  una  complicación  infecciosa.  Los  factores  que
se asociaron  al  desarrollo  de  complicaciones  infecciosas  fueron  la  historia  de  cultivos  de  orina
positivos  en  los  3  an˜os  previos  a  la  biopsia,  la  presencia  de  sonda  transuretral  al  momento  de
la biopsia,  hospitalizaciones  en  el  ultimo  mes  antes  de  la  biopsia,  así  como  un  cultivo  de  orina
positivo en  los  laboratorios  pre-biopsia,  incluso  después  de  haber  recibido  tratamiento  dirigido
por antibiograma.
Conclusiones:  Los  pacientes  deben  estar  conscientes  del  riesgo  de  complicaciones,  particular-
mente si  presentan  los  factores  de  riesgo  mencionados.  Piperacilina/tazobactam  en  dosis  única
es una  buena  opción  de  proﬁlaxis  pre-biopsia  particularmente  en  regiones  con  alta  tasa  de
resistencia antimicrobiana.
© 2015  The  Authors.  Publicado  por  Masson  Doyma  México  S.A.  en  nombre  de  Sociedad
Mexicana  de  Urología.  Este  es  un  artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Currently,  prostate  biopsy  (PB)  is  the  standard  method
for  conﬁrming  the  diagnosis  of  prostate  cancer  (PCa).  The
implementation  of  widespread  screening  with  prostate-
speciﬁc  antigen  (PSA)  has  increased  the  number  of  PBs  over
the  last  decades.1 A  rising  PSA  and/or  suspicious  digital  rec-
tal  exam  (DRE)  are  the  most  frequent  indications  for  a PB.2
Other  indications  include  persistently  elevated  PSA  with  a
low  PSA  free/total  ratio,  increased  PSA  velocity,  PSA  dupli-
cation  time  or  PSA  density,  the  histopathologic  ﬁnding  of
atypical  small  acini  proliferation  (ASAP),  prostatic  intraep-
ithelial  neoplasia  (PIN),  and  active  surveillance.3,4
PB  can  be  performed  either  transrectally  or  transper-
ineally  under  ultrasound  or  magnetic  resonance  guidance.
The  number  of  cores  taken  depends  on  prostate  size,  his-
tory  of  previous  biopsies,  and  patient  age.  In  our  center,
we  usually  perform  ultrasound-guided  transrectal  prostate
biopsies  (TRPB)  with  12--18  cores  at  initial  biopsy.5
The  reported  complication  rate  of  TRPB  is  variable:
bleeding  occurs  in  up  to  50%  of  cases,  although  it  is
usually  clinically  irrelevant.6 Nevertheless,  serious  infec-
tious  complications  develop  in  2--6%  of  cases,  of  which
nearly  4%  require  hospitalization  and  treatment  within
30  days  after  the  procedure.  Given  the  severity  of
infectious  complications,  some  strategies  have  been  rec-
ommended  in  order  to  lower  their  frequency,  including
the  use  of  prophylactic  antibiotics.7 However,  there  is  still
controversy  regarding  the  adequate  type  and  dosage  of
antibiotic.  Quinolones  are  the  most  widely  recommended,
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oecause  they  have  good  penetration  into  prostatic  tissue.2
nfortunately,  quinolone  resistance  rates  have  increased
igniﬁcantly.8 In  Latin  America  and  other  developing  areas
round  the  world,  the  resistance  rates  to  quinolones  and
ephalosporins  have  reached  alarming  ﬁgures.  For  this  rea-
on  since  2008,  we  have  found  it  necessary  to  use  an
lternative  prophylactic  strategy  based  on  a  single  i.v.
ose  of  piperacillin/tazobactam  (P--T).9 In  this  study  we
escribed  the  complications  of  TRPB,  emphasizing  infectious
omplications,  with  the  use  of  this  prophylactic  regime.
ethods
e  performed  a retrospective  study  on  men  that  underwent
RPB  from  January  2008  to  June  2013  at  our  department.
atients  without  complete  clinical  records  were  excluded.
e  analyzed  clinical,  laboratorial,  and  pathological  data,
s  well  as  follow-up  information.  Previous  evaluation  in  all
atients  included  PSA,  complete  blood  cell  count,  blood
hemistry,  coagulation  tests,  urinalysis,  and  urine  culture.
As  preparation,  all  patients  received  the  indication  to
pply  a  micro-enema  the  night  before  and  the  morning  of
he  procedure.  Prophylaxis  with  a  single  i.v.  dose  of  P--T  4.5  g
as  administered  30--60  min  before  biopsy.  After  measuring
rostate  and  transition  zone  volumes,  core  biopsies  were
btained  with  semi-automatic  equipment  (BARD® MAGNUM®
eusable  Core  Biopsy  System)  and  an  18-Gauge  thru-cut  nee-
le  in  a  systematic  fashion  (12--18  cores  for  the  ﬁrst  TRPB
r  extended  protocol  for  subsequent  procedures).
2 J.O.  Herrera-Caceres  et  al.
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Figure  1  Germs  isolated  in  the  last  urine  culture  before
biopsy.
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Perioperative  complications  were  registered  during  the
rocedure  and  stated  in  the  surgical  report.  Outpatient  vis-
ts  were  scheduled  1  week  and  1  month  after  biopsy.  All
atients  were  advised  about  possible  symptoms  and  to  go  to
he  emergency  room  (ER),  if  necessary,  in  the  case  of  further
omplications.  Perioperative  and  early  complications  were
lassiﬁed  according  to  the  Clavien--Dindo  system.10
We  intentionally  reviewed  the  past  urologic  history  of  the
atients,  looking  for  positive  urine  cultures  within  3  years
efore  biopsy  and  its  association  to  urinary  tract  infection
UTI)  or  resistant  strains  after  TRPB.  A  univariate  analysis
as  performed  to  ﬁnd  variables  related  to  the  development
f  infectious  complications,  and  statistical  analysis  was  done
sing  the  IBM® SPSS® v.  20  package.
Because  of  the  retrospective  nature  of  the  study,
thics  committee  approval  was  not  necessary.  Nevertheless,
atient  data  conﬁdentiality  was  maintained  and  there  was
o  violation  of  the  Helsinki  Declaration.
esults
 total  of  543  men  that  underwent  TRPB  were  included
n  the  study.  Mean  age  was  65  ±  7.51  years.  Median  PSA
as  7.49  (0.22--3000)  ng/ml.  Lower  urinary  tract  symptoms
LUTS)  were  reported  by  68%  of  the  patients  and  66%  were
nder  -blocker  therapy.  The  most  frequent  comorbidities
ere  diabetes  mellitus  in  165  men  (30.4%)  and  high  blood
ressure  in  258  (47.4%).  Thirty-seven  patients  (6.8%)  had  a
ransurethral  indwelling  catheter  at  the  time  of  TRPB  and
4  (6.3%)  had  a  previous  hospital  admission  within  a month
efore  TRPB.
A total  of  436  men  (80.3%)  underwent  ﬁrst-time  TRPB,
hereas  107  (19.7%)  underwent  subsequent  biopsy.  Indi-
ations  for  TRPB  included  high  PSA  in  341  cases  (62.7%),
uspicious  DRE  in  33  (6.1%),  both  an  elevated  PSA  and  suspi-
ious  DRE  in  143  (26.3%),  ASAP  in  11  (2%),  active  surveillance
n  6 (1.1%),  and  not  speciﬁed  in  9  (1.6%).  PSA  value  was
10  ng/ml  in  246  (45.3%)  patients;  between  10  and  20  ng/ml
n  81  (14.9%);  >20  ng/ml  in  31  (5.7%);  and  missing  in  185
ases.  Mean  prostate  volume  was  51.46  ±  29.1  cc.  Twelve-
ore  biopsy  was  performed  in  300  men  (55.8%),  more  than
2  in  234  (43.5%)  patients,  fewer  than  12  in  4  cases  (0.8%),
nd  not  speciﬁed  in  5.All  patients  had  a  urine  culture  before  TRPB,  of  which  35
6.4%)  were  positive.  Treatment  was  completed  according  to
esistance  pattern  (Fig.  1).  We  found  that  217  (39.9%)  of  the
atients  had  2  or  more  urine  cultures  within  3  years  before
o
a
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Table  1  Clavien--Dindo  classiﬁcation  of  complications  within  a  m
Clavien--Dindo  classiﬁcation  No  =  74  (13.63%)
Grade  I  66  (12.15%)  
Grade II  5  (0.92%)  
Grade III  3  (0.55%)  
Grade IIIa  3  (0.55%)
Grade  IIIb  0
Grade  IV  0
Grade  V  0Figure  2  Complications  within  a  month  after  biopsy.
he  procedure;  48  (22.1%)  of  them  had  at  least  1  positive
rine  culture  within  that  period.
Only  3  patients  had  intraoperative  complications:  1
atient  had  transient  bradycardia,  1  had  transient  hypoten-
ion  (both  required  interruption  of  the  procedure)  and  1
atient  presented  with  rash  presumably  due  to  P--T  allergic
eaction,  in  whom  the  procedure  was  completed  safely.
During  the  ﬁrst  month,  74  patients  (13.6%)  reported  at
east  one  complication,  for  a  total  of  92  events  (Fig.  2).
he  Clavien--Dindo  classiﬁcation  is  reported  in  Table  1.
wo  patients  had  acute  urinary  retention  (0.36%)  and  23
4.2%)  had  infectious  complications  including  acute  prostati-
is,  orchiepididymitis,  pyelonephritis,  or  fever.  Sixty-nine
12.8%)  patients  had  a  urine  culture  within  the  ﬁrst  month,
f  which  19  were  positive  (27.5%).  Two  (0.36%)  patients  were
dmitted  to  receive  i.v.  antibiotics.
The  univariate  analysis  showed  that  a  previous  history
f  positive  urine  cultures  within  3  years,  the  presence  of
onth  after  biopsy.
No  modiﬁcations  in  treatment
Antibiotic  treatment  (2  required  hospitalization)
Transurethral  catheterism
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Table  2  Univariate  analysis  of  factors  related  to  infectious  complications.
Variables  HR  95%  CI  p
History  of  at  least  one  positive  urine  culture  within  3  years  prior  to  the  biopsy  4.061  1.48--11.13  0.003
Transurethral  catheter  at  the  time  of  biopsy  6.235  2.42--16.09  0.001
Hospitalization  within  a  month  prior  to  the  biopsy  3.051  0.99--9.46  0.05
A positive  urine  culture  immediately  before  the  biopsy,  even  after  guided  treatment  5.007  1.87--13.42  0.001
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ctransurethral  indwelling  catheter  at  the  time  of  the  pro-
cedure,  and  preoperative  positive  urine  culture  despite
antibiotic  therapy  selected  according  to  resistance  pat-
tern  were  factors  associated  with  infectious  complications
(Table  2).
PCa  was  diagnosed  in  172  cases  (31.8%),  affecting  both
prostatic  lobes  in  91  (52.9%)  and  2  or  more  cores  in  93  (54%).
A  Gleason  score  of  6  was  diagnosed  in  47%  of  cases.
According  to  the  D’Amico  risk  group  classiﬁcation,  59
(34.7%)  cases  were  low  risk  tumors,  61  (35.9%)  were  inter-
mediate  risk,  and  50  (29.4%)  were  high  risk.  Classiﬁcation
could  not  be  completed  in  two  patients  due  to  insufﬁcient
data.  Other  diagnoses  included  chronic  prostatitis  in  331
(61.3%)  patients;  atrophy  in  283  (52.4%);  benign  prostatic
hyperplasia  in  391  (73.1%);  PIN  in  15  (2.8%);  and  ASAP  in  10
(1.8%).
Discussion
In  this  retrospective  analysis  of  TRPB,  we  found  that  the
overall  rate  of  early  complications  was  low  (13.6%).  Although
hematuria  was  frequently  reported,  it  did  not  require
therapeutic  intervention.  Other  well-known  complications
included  hematospermia  and  rectorrhagia.
Infectious  complications  are  particularly  relevant,  given
their  life-threatening  potential.  The  prophylactic  regime
with  P--T  allowed  us  to  control  this  type  of  sequel  (4.2%)
during  the  ﬁrst  month.  All  patients  were  successfully  treated
and  only  two  patients  required  hospital  admission  to  com-
plete  their  treatment.  Sanders  and  Buchan  analyzed  1421
TRPBs  and  reported  a  hospitalization  rate  of  2.8%  (40  cases)
within  the  ﬁrst  month  after  biopsy.  They  used  a  4-day  course
of  antibiotics  as  prophylaxis,  mostly  with  ciproﬂoxacin.  More
than  50%  of  isolated  Escherichia  coli  strains  after  biopsy
were  resistant  to  quinolones.11 Another  retrospective  study
performed  in  two  hospitals  in  London,  UK,  reported  2.1%
of  infectious  complications  requiring  admission  to  the  ER.
They  used  a  5-day  prophylactic  course  of  ciproﬂoxacin  and  a
single  i.v.  dose  of  amikacin  before  the  procedure.  The  major-
ity  of  isolated  microorganisms,  particularly  those  causing
bacteremia,  were  ESBL-producing  strains  that  were  also
resistant  to  quinolones.12
We  and  others  have  previously  reported  the  experience
with  a  single  dose  of  PT  as  antimicrobial  prophylaxis9,13 or
in  combination  with  quinolones.14 The  use  of  a  single  dose
of  antibiotic  prophylaxis  is  an  appealing  strategy,15 partic-
ularly  in  countries  with  a  higher  prevalence  of  resistant
microorganisms.  In  recent  years,  our  institutional  resistance
rate  has  risen,  with  57%  of  E.  coli  strains  being  resistant  to
quinolones.16,17
i
p
tOur  results  demonstrate  that  past  medical  history  with  a
ocus  on  infectious  disease  and  urological  issues  is  of  the
tmost  relevance.  As  previously  shown,  the  presence  of
 transurethral  indwelling  catheter  at  the  time  of  biopsy
as  strongly  associated  with  the  development  of  infec-
ious  complications.  Therefore,  if  possible,  a  TRPB  should
e  avoided  while  patients  are  using  this  device  or  deferred
ntil  completion  of  proper  antibiotic  therapy.  Other  non-
odiﬁable  risk  factors  for  infectious  complications  include
 previous  positive  urine  culture  or  UTI  within  a  3-year  time
eriod  before  biopsy.  Modiﬁable  risk  factors  are  positive
rine  culture  immediately  before  TRPB  or  recent  hospital
dmission.  The  former  requires  properly  selected  antibiotic
herapy  based  on  an  antibiotic  susceptibility  test  and  the
elay  of  TRPB  until  a  negative  urine  culture  is  obtained.
oreover,  it  would  be  advisable  to  perform  biopsy  at  least
 month  after  discharge  from  previous  hospital  admission.
n  the  other  hand,  some  authors  have  demonstrated  the
ole  of  rectal  swabs  in  providing  targeted  antimicrobial
rophylaxis,  thus  decreasing  the  incidence  of  infectious
omplications.18
Overall,  the  infection  rate  we  found  was  consistent
ith  rates  in  the  literature.  However,  our  ﬁgure  is  of
aramount  relevance,  considering  that  with  this  strategy  we
chieved  infectious  complication  control  similar  to  that  in
he  developed  countries,  where  the  use  of  quinolones  or
ephalosporins  is  still  safe  for  PB  prophylaxis.  Even  though
hese  data  suggest  that  a  single  i.v.  dose  of  P--T  does  not
rovide  better  prophylaxis  than  other  regimens,  we  believe
t  is  an  excellent  option  for  clinical  practice  in  world  regions
ther  than  the  US  and  Europe,  where  resistance  rates  make
he  use  of  quinolones  prohibitive.  Furthermore,  besides  hav-
ng  a  broader-spectrum,  in  comparison  with  cephalosporins,
--T  induces  to  a  lesser  extent  the  expression  of  ESBL-
roducing  strains.19
Our  study  has  some  limitations,  mostly  due  to  the  retro-
pective  nature  of  the  investigation.  Moreover,  the  inclusion
f  a  comparative  group  receiving  a  different  antibiotic
ould  be  desirable.  However,  the  strength  of  this  investi-
ation  is  the  fact  that  all  patients  underwent  a  homogenous
valuation,  including  a  urine  culture  with  an  antibiotic  sus-
eptibility  test  prior  to  biopsy  and  all  received  the  same
ntibiotic  regime.  Moreover,  other  advantages  include  the
lose  follow-up  based  on  electronic  records  and  the  pro-
essing  of  all  urine  cultures  at  our  institution,  as  well  as
he  description  of  risk  factors  associated  with  infectious
omplications.We  believe  a  single  i.v.  dose  of  piperacillin--tazobactam
s  an  alternative  for  TRPB  in  an  environment  with  a  high
revalence  of  quinolone  resistance.  Being  a  single  dose
reatment  with  a  broad  spectrum  and  lower  induction  of
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176  
esistant  strains,  complication  rates  remain  low.  Before  per-
orming  a  TRPB,  it  is  advisable  to  acknowledge  the  following
isk  factors  for  infectious  complications:  a  previous  history
f  positive  urine  cultures  within  3  years,  the  presence  of
ransurethral  catheter  at  the  time  of  the  procedure,  hospi-
al  admission  within  the  previous  month,  and  preoperative
ositive  urine  culture  despite  antibiotic  therapy  selected
ccording  to  resistance  pattern.  Future  research  should  aim
o  analyze  these  factors  in  a  prospective  fashion.  Patients
ith  a  positive  culture  should  conﬁrm  urine  sterility  after
ntibiotic  treatment.
onclusions
rostate  biopsies  are  a  necessary  procedure  for  the  diag-
osis  of  PCa,  but  urologists  and  patients  must  be  aware  of
he  risks.  If  possible,  patients  should  wait  if  they  have  had
ecent  hospitalization  and  transurethral  catheters  should
e  taken  out.  It  is  recommendable  to  have  a  conﬁrmatory
rine  culture,  even  if  patients  have  taken  proper  antibi-
tic  treatments.  Patients  with  a  history  of  previous  urine
nfections  must  be  aware  of  the  higher  risk  for  infectious
omplications.
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